Gmax has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the antibody candidates with excellent drugability and developability.
GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial Hangzhou, China. Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension (PAH). ...
2022年11月30日,Gmax Biopharm, LLC 下属的鸿运华宁(杭州)生物医药有限公司宣布,重组抗人 GLP-1 受体人源化单克隆抗体(GMA102)注射液用于二甲双胍治疗血糖控制不佳的2型糖尿病(T2DM)受试者III期临床研究完成首例受试者给药。 本研究是一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病受试者中开展的为期52周的...
Gmax Biopharm International Limited 仍注册 中国香港 2025-03更新 商业登记号码:73088425 企查查编码:QHK0WDABBF 成立日期:2021-06-16 办事处地址:5/F, MANULIFE PLACE, 348 KWUN TONG ROAD, KOWLOON, HONG KONG 登记信息 商业登记号码 73088425 企业名称 ...
【杭州鸿运华宁生物医药工程有限公司(Gmax Biopharm)招聘】杭州鸿运华宁寻觅一位临床精英,共同推进新药项目。详情请见:O网页链接另可前往医药魔方“找职位”查看更多职位:O网页链接或扫二维码关注医药魔方微信,实时接收更多医药公司招聘信息。
网站www.gmaxbiopharm.com详情 上次更新时间:2024/5/22 2:05:03立即更新 www.gmaxbiopharm.com是鸿运华宁(杭州)生物医药有限公司旗下网站,网站成立于2010年12月3日,该网站属于综合其他行业。网站主要内容为:gmax biopharm llc.,gpcrs,gpcr mab discovery platform,monoclonal antibody development platform等。网站前端...
Jing, Shuqian (Hangzhou, CN) Application Number: 15/547727 Publication Date: 01/04/2018 Filing Date: 02/03/2016 Export Citation: Click for automatic bibliography generation Assignee: Gmax Biopharm LLC. (Hangzhou, CN) International Classes: ...
gmaxbiopharm.com备案信息 2019-05-27---2024-09-25 浙ICP备11006114号-1 最新域名查询 www.6wgd2pz.com 49910.com www.j3fk.com www.6673ck.com www.co9oetk.com 775ee.com 1155tv.com tt66y.com 212125.com www60949.com japan060102.ippa.com www.diefa5.com www.8n0yakv.com www.0aql4...
Gmax has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the antibody candidates with excellent drugability and developability.